Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • boxcarlong boxcarlong Jun 10, 2010 9:42 AM Flag

    Lets Do some MATH

    Yes I can agree on those numbers. I'am just being very very concervative on the patient population
    penetration rate ( based on 9M USA, 100M Worldwide) and the cost per patient to show how easy it will be to generate $1B in top-line sales for just ENDO. The cost to treat ENDO in the USA alone is $20B on an annual basis.

    The Elagolix partnership is going to be a significant game changer for NBIX. I don't think most investors have realized that. IMO, NBIX moves from a tier 4 biotech Co a Tier 2 co and tier 1 apon Elagolix FDA approval in Q4 FY13/ Q1 FY14. Than a follow on indication in FY15 for Uterin F.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NBIX
53.25-0.69(-1.28%)Sep 26 4:00 PMEDT